1,153 results match your criteria cmv-specific cells


Immunotherapy with adoptive cytomegalovirus-specific T cells transfer: Summarizing latest gene engineering techniques.

Health Sci Rep 2021 Sep 8;4(3):e322. Epub 2021 Jul 8.

Hematopoietic Stem Cell Research Center Shahid Beheshti University of Medical Sciences Tehran Iran.

Cytomegalovirus (CMV) infection remains a major complication following allogeneic hematopoietic stem cell transplantation (HSCT). T cell response plays a critical role in inducing long-term immunity against CMV infection/reactivation that impairs during HSCT. Adoptive T cell therapy (ACT) via transferring CMV-specific T cells from a seropositive donor to the recipient can accelerate virus-specific immune reconstitution. Read More

View Article and Full-Text PDF
September 2021

Circulatory follicular helper T lymphocytes associate with lower incidence of CMV infection in kidney transplant recipients.

Am J Transplant 2021 Jun 21. Epub 2021 Jun 21.

Instituto de Investigación Biomédica Hospital 12 de Octubre (imas12), Madrid, Spain.

Primary infection and/or reactivation of cytomegalovirus (CMV) in kidney transplant recipients (KTR) favor rejection and mortality. T follicular helper cells (TFH) could contribute to protection against CMV. Circulatory TFH (cTFH) were studied pretransplant and early posttransplant in 90 CMV seropositive KTR not receiving antithymocyte globulin or antiviral prophylaxis, followed-up for 1 year. Read More

View Article and Full-Text PDF

CMV exposure drives long-term CD57+ CD4 memory T cell inflation following allogeneic stem cell transplant.

Blood 2021 Jun 3. Epub 2021 Jun 3.

Fred Hutchinson Cancer Research Center, Seattle, Washington, United States.

Donor and recipient cytomegalovirus (CMV) serostatus correlate with transplant related mortality that is associated with reduced survival following allogeneic stem cell transplant (SCT). Prior epidemiologic studies have suggested that CMV seronegative recipients (R-) receiving a CMV seropositive graft (D+) experience inferior outcomes compared to other serostatus combinations, an observation that appears independent of viral reactivation. We therefore investigated the hypothesis that prior donor CMV exposure irreversibly modifies immunologic function after SCT. Read More

View Article and Full-Text PDF

Viral Molecular Mimicry Influences the Antitumor Immune Response in Murine and Human Melanoma.

Cancer Immunol Res 2021 Jun 8. Epub 2021 Jun 8.

Laboratory of ImmunoViroTherapy, Drug Research Program, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.

Molecular mimicry is one of the leading mechanisms by which infectious agents can induce autoimmunity. Whether a similar mechanism triggers an antitumor immune response is unexplored, and the role of antiviral T cells infiltrating the tumor has remained anecdotal. To address these questions, we first developed a bioinformatic tool to identify tumor peptides with high similarity to viral epitopes. Read More

View Article and Full-Text PDF

CMV-Specific Cell-Mediated Immunity in Immunocompetent Adults with Primary CMV Infection: A Case Series and Review of the Literature.

Viruses 2021 May 1;13(5). Epub 2021 May 1.

Microbiology Unit, Department of Specialized, Experimental and Diagnostic Medicine, IRCCS St. Orsola Polyclinic, University of Bologna, 40138 Bologna, Italy.

Cytomegalovirus-specific cell-mediated immunity (CMV-CMI) in actively infected healthy immunocompetent hosts has been poorly investigated. Conversely, correlates of maternal protective immunity for the fetus after primary infection in pregnancy continue to be studied. The kinetics and magnitude of CMV-specific CMI in immunocompetent primary CMV-infected adults are described. Read More

View Article and Full-Text PDF

Latent CMV Infection Is Associated With Lower Influenza Virus-Specific Memory T-Cell Frequencies, but Not With an Impaired T-Cell Response to Acute Influenza Virus Infection.

Front Immunol 2021 5;12:663664. Epub 2021 May 5.

Center for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, Netherlands.

Latent infection with cytomegalovirus (CMV) is assumed to contribute to the age-associated decline of the immune system. CMV induces large changes in the T-cell pool and may thereby affect other immune responses. CMV is expected to impact especially older adults, who are already at higher risk of severe disease and hospitalization upon infections such as influenza virus (IAV) infection. Read More

View Article and Full-Text PDF

Low frequency of cytomegalovirus (CMV) disease despite high prevalence of CMV viraemia in patients with advanced HIV infection: a clinical and immunological 48-week follow-up study.

HIV Med 2021 May 17. Epub 2021 May 17.

Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Objectives: The aim of the study was to investigate the dynamics of cytomegalovirus (CMV) replication and CMV-specific immune response recovery after antiretroviral treatment (ART) initiation in patients with advanced HIV infection.

Methods: A prospective observational study of patients with HIV infection and CD4 counts of < 100 cells/µL was carried out (September 2015 to July 2018). HIV viral load (VL), CD4 count and CMV VL were determined by quantitative polymerase chain reaction (PCR) at baseline and at 4, 12, 24 and 48 weeks, and CMV-specific immune response was determined by QuantiFERON-CMV assay at baseline and 48 weeks. Read More

View Article and Full-Text PDF

Impaired T-cell and antibody immunity after COVID-19 infection in chronically immunosuppressed transplant recipients.

bioRxiv 2021 May 4. Epub 2021 May 4.

Assessment of T-cell immunity to the COVID-19 coronavirus requires reliable assays and is of great interest, given the uncertain longevity of the antibody response. Some recent reports have used immunodominant spike (S) antigenic peptides and anti-CD28 co-stimulation in varying combinations to assess T-cell immunity to SARS-CoV-2. These assays may cause T-cell hyperstimulation and could overestimate antiviral immunity in chronically immunosuppressed transplant recipients, who are predisposed to infections and vaccination failures. Read More

View Article and Full-Text PDF

Is It Feasible to Use CMV-Specific T-Cell Adoptive Transfer as Treatment Against Infection in SOT Recipients?

Front Immunol 2021 23;12:657144. Epub 2021 Apr 23.

National Center for Microbiology, Instituto de Salud Carlos III, Majadahonda, Spain.

During the last decade, many studies have demonstrated the role of CMV specific T-cell immune response on controlling CMV replication and dissemination. In fact, it is well established that transplanted patients lacking CMV-specific T-cell immunity have an increased occurrence of CMV replication episodes and CMV-related complications. In this context, the use of adoptive transfer of CMV-specific T-cells has been widely investigated and applied to Hematopoietic Stem Cell Transplant patients and may be useful as a therapeutic alternative, to reconstitute the CMV specific T-cell response and to control CMV viremia in patients receiving a transplantation. Read More

View Article and Full-Text PDF

Cytomegalovirus infection is associated with an increase in aortic stiffness in older men which may be mediated in part by CD4 memory T-cells.

Theranostics 2021 31;11(12):5728-5741. Epub 2021 Mar 31.

Department of Clinical and Experimental Medicine, Brighton and Sussex Medical School, Brighton, United Kingdom.

Human Cytomegalovirus (CMV) infection is associated with atherosclerosis, higher cardiovascular disease (CVD) risk, and an increase in memory T-cells (T). T-cells have also been implicated in CVD, independently of CMV infection. To better understand the CMV-associated CVD risk, we examined the association between CMV (IgG) serostatus and central aortic (carotid-to-femoral) pulse wave velocity (cfPWV), an early, independent predictor of CVD. Read More

View Article and Full-Text PDF

Ocular Outcomes after Treatment of Cytomegalovirus Retinitis Using Adoptive Immunotherapy with Cytomegalovirus-Specific Cytotoxic T Lymphocytes.

Ophthalmol Retina 2021 Apr 20. Epub 2021 Apr 20.

Department of Ophthalmology, Weill Cornell Medical College, New York, New York. Electronic address:

Purpose: To describe ocular outcomes in eyes with cytomegalovirus (CMV) retinitis treated with adoptive immunotherapy using systemic administration of CMV-specific cytotoxic Tlymphocytes (CMV-specific CTLs).

Design: Retrospective cohort study.

Participants: Patients with active CMV retinitis evaluated at a tertiary care academic center. Read More

View Article and Full-Text PDF

Impact of maternal engrafted cytomegalovirus-specific CD8 T cells in a patient with severe combined immunodeficiency.

Clin Transl Immunology 2021 13;10(4):e1272. Epub 2021 Apr 13.

Graduate School of Medical Science and Engineering Korea Advanced Institute of Science and Technology (KAIST) Daejeon Republic of Korea.

Objectives: In patients with severe combined immunodeficiency (SCID), the immune system often fails to eradicate maternal cells that enter the foetus via the placenta, resulting in transplacental maternal engraftment (TME) syndrome. However, the clinical significance of TME has not been comprehensively elucidated.

Methods: Here, we describe a patient with SCID with a novel frameshift mutation associated with maternal engrafted CD8 T cells that had been expanded by viral infection. Read More

View Article and Full-Text PDF

Association of CMV-specific T-cell immunity and risk of CMV infection in lung transplant recipients.

Clin Transplant 2021 06 3;35(6):e14294. Epub 2021 Apr 3.

Department of Medicine V, Comprehensive Pneumology Center (CPC-M), German Center for Lung Research (DZL), University Hospital, LMU Munich, Munich, Germany.

Background: Protecting against CMV infection and maintaining CMV in latent state are largely provided by CMV-specific T-cells in lung transplant recipients. The aim of the study was to assess whether a specific T-cell response is associated with the risk for CMV infection in seronegative patients who are at high risk for delayed CMV infection.

Methods: All CMV-seronegative recipients (R-) from CMV-seropositive donors (D+) between January 2018 and April 2019 were included and retrospectively screened for CMV infection before and after assessment of CMV-specific cell-mediated immunity. Read More

View Article and Full-Text PDF

Undernutrition and Hypoleptinemia Modulate Alloimmunity and CMV-specific Viral Immunity in Transplantation.

Transplantation 2021 Mar 10. Epub 2021 Mar 10.

Department of Pediatrics, Duke University Medical Center, Durham, NC. Department of Immunology, Duke University School of Medicine, Durham, NC. Department of Surgery, Duke University Medical Center, Durham, NC.

Background: Immunological mechanisms linking undernutrition to infection and the alloimmune response are poorly understood in transplantation. We aimed to determine how undernutrition and hypoleptinemia impact T cell allo- and CMV viral specific immunity in a murine model.

Methods: Fed, fasted for 48 hours (model of undernutrition), and fasted with leptin injections (leptin rescue) C57BL/6 mice received skin grafts from either C57BL/6 (syngeneic) or BALB/c (allogeneic) mice donors. Read More

View Article and Full-Text PDF

Cytomegalovirus-Specific Immunity Recovers More Slowly after Cord Blood Transplantation Compared with Matched Sibling Donor Allogeneic Transplantation.

Transplant Cell Ther 2021 Feb 21;27(2):187.e1-187.e4. Epub 2020 Dec 21.

Department of Medicine. University of Minnesota, Minneapolis, Minnesota.

Background: Rapid quantitative recovery of NK cells but slower recovery of T-cell subsets along with frequent viral infections are reported after umbilical cord blood (UCB) compared with matched sibling donor (MSD) hematopoietic cell transplantation (HCT). However, it remains unclear whether increased propensity for viral infections is also a result of slower recovery of virus-specific immunity after UCB as compared to MSD HCT.

Objectives: We examined the differences in the function of virus-specific peripheral blood mononuclear cells (PBMC) after UCB (N=17) vs. Read More

View Article and Full-Text PDF
February 2021

Comparison of Cytomegalovirus-Specific Immune Cell Response to Proteins versus Peptides Using an IFN-γ ELISpot Assay after Hematopoietic Stem Cell Transplantation.

Diagnostics (Basel) 2021 Feb 15;11(2). Epub 2021 Feb 15.

Department of Internal Medicine III, Hematology and Oncology, University Medical Center Regensburg, 93053 Regensburg, Germany.

Cytomegalovirus (CMV) infection is a major cause of morbidity and mortality following hematopoietic stem cell transplantation (HSCT). Measuring CMV-specific cellular immunity may improve the risk stratification and management of patients. IFN-γ ELISpot assays, based on the stimulation of peripheral blood mononuclear cells with CMV pp65 and IE-1 proteins or peptides, have been validated in clinical settings. Read More

View Article and Full-Text PDF
February 2021

Single-cell analysis shows that adipose tissue of persons with both HIV and diabetes is enriched for clonal, cytotoxic, and CMV-specific CD4+ T cells.

Cell Rep Med 2021 Feb 16;2(2):100205. Epub 2021 Feb 16.

Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.

Persons with HIV are at increased risk for diabetes mellitus compared with individuals without HIV. Adipose tissue is an important regulator of glucose and lipid metabolism, and adipose tissue T cells modulate local inflammatory responses and, by extension, adipocyte function. Persons with HIV and diabetes have a high proportion of CX3CR1 GPR56 CD57 (C-G-C) CD4 T cells in adipose tissue, a subset of which are cytomegalovirus specific, whereas individuals with diabetes but without HIV have predominantly CD69 CD4 T cells. Read More

View Article and Full-Text PDF
February 2021

Virus-specific memory T cell responses unmasked by immune checkpoint blockade cause hepatitis.

Nat Commun 2021 03 4;12(1):1439. Epub 2021 Mar 4.

Department of Dermatology, University Hospital Regensburg, Regensburg, Germany.

Treatment of advanced melanoma with combined PD-1/CTLA-4 blockade commonly causes serious immune-mediated complications. Here, we identify a subset of patients predisposed to immune checkpoint blockade-related hepatitis who are distinguished by chronic expansion of effector memory CD4 T cells (T cells). Pre-therapy CD4 T cell expansion occurs primarily during autumn or winter in patients with metastatic disease and high cytomegalovirus (CMV)-specific serum antibody titres. Read More

View Article and Full-Text PDF

PD-1 is imprinted on cytomegalovirus-specific CD4+ T cells and attenuates Th1 cytokine production whilst maintaining cytotoxicity.

PLoS Pathog 2021 03 4;17(3):e1009349. Epub 2021 Mar 4.

Institute of Immunology & Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.

PD-1 is expressed on exhausted T cells in cancer patients but its physiological role remains uncertain. We determined the phenotype, function and transcriptional correlates of PD-1 expression on cytomegalovirus-specific CD4+ T cells during latent infection. PD-1 expression ranged from 10-85% and remained stable over time within individual donors. Read More

View Article and Full-Text PDF

Safety and efficacy of the low-dose memory (CD45RA-depleted) donor lymphocyte infusion in recipients of αβ T cell-depleted haploidentical grafts: results of a prospective randomized trial in high-risk childhood leukemia.

Bone Marrow Transplant 2021 07 16;56(7):1614-1624. Epub 2021 Feb 16.

Department of Hematopoietic Stem Cell Transplantation, Dmitriy Rogachev National Medical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.

Depletion of αβ T cells from the graft prevents graft-vs.-host disease (GVHD) and improves outcome of HSCT from haploidentical donors. In a randomized trial, we aimed to evaluate the safety and efficacy of low-dose memory (CD45RA-depleted) donor lymphocytes (mDLI) after HSCT with αβ T-cell depletion. Read More

View Article and Full-Text PDF

Case Report: Management of a Multidrug-Resistant CMV-Strain in a Renal Transplant Recipient by High-Dose CMV-Specific Immunoglobulins, Modulation in Immunosuppression, and Induction of CMV-Specific Cellular Immunity.

Front Immunol 2020 25;11:623178. Epub 2021 Jan 25.

Transplant Nephrology/Department of Internal Medicine D, University Hospital Münster, Westphalian Wilhelm's University Münster, Münster, Germany.

The management of multidrug-resistant strains of cytomegalovirus after solid organ transplantation is challenging. This case report demonstrates the successful treatment of a multidrug-resistant strain of cytomegalovirus that may represent a valuable option for problematic cases. This report illustrates the emergence of a multidrug-resistant cytomegalovirus (CMV) UL54 mutant strain in a renal transplant recipient with severe lymphopenia and thrombocytopenia. Read More

View Article and Full-Text PDF

Peptide Vaccination against Cytomegalovirus Induces Specific T Cell Response in Responses in CMV Seronegative End-Stage Renal Disease Patients.

Vaccines (Basel) 2021 Feb 6;9(2). Epub 2021 Feb 6.

Department of Internal Medicine V, University of Heidelberg, 69117 Heidelberg, Germany.

Introduction: Cytomegalovirus (CMV) reactivation occurs in seronegative patients after solid organ transplantation (SOT) particularly from seropositive donors and can be lethal. Generation of CMV-specific T cells helps to prevent CMV reactivation. Therefore, we initiated a clinical phase I CMVpp65 peptide vaccination trial for seronegative end-stage renal disease patients waiting for kidney transplantation. Read More

View Article and Full-Text PDF
February 2021

Immunologic monitoring of cytomegalovirus (CMV) enzyme-linked immune absorbent spot (ELISPOT) for controlling clinically significant CMV infection in pediatric allogeneic hematopoietic stem cell transplant recipients.

PLoS One 2021 5;16(2):e0246191. Epub 2021 Feb 5.

Department of Pediatrics, Asan Medical Center Children's hospital, University of Ulsan College of Medicine, Seoul, Republic of Korea.

The dynamics of recovery of cytomegalovirus (CMV)-specific cell-mediated immunity (CMI) and its impact on controlling clinically significant CMV infections following hematopoietic stem cell transplant (HSCT) are rarely reported in pediatric HSCT recipients. In this study, dynamics of recovery of CMV-specific CMI and its clinical significance in controlling CMV viremia and clinically significant CMV infections were assessed in pediatric allogeneic HSCT recipients. All subjects underwent CMV pp65- and IE1-specific enzyme-linked immune absorbent spot (ELISPOT) assays just before transplantation and then monthly until the detection of CMV-specific CMI with ≥ 5 spot-forming cells (SFC) / 2. Read More

View Article and Full-Text PDF

Cytomegalovirus management after allogeneic hematopoietic stem cell transplantation: A mini-review.

J Microbiol Immunol Infect 2021 Jun 13;54(3):341-348. Epub 2021 Jan 13.

Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; Department of Hematological Oncology, National Taiwan University Cancer Center, Taipei, Taiwan. Electronic address:

Because of the high incidence of cytomegalovirus (CMV) seropositivity in the population, CMV infection is a common and severe complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in Taiwan. Here we propose a CMV management strategy for patients undergoing allo-HSCT from the Taiwanese perspective, which focuses on the epidemiology, diagnosis, monitoring, prophylaxis, and treatment of CMV infection after allo-HSCT. In terms of CMV monitoring, weekly CMV monitoring with the COBAS® AmpliPrep system is the standard approach because the pp65 CMV antigenemia assay has a lower sensitivity than CMV monitoring with the COBAS® AmpliPrep system. Read More

View Article and Full-Text PDF

Adoptive therapy with CMV-specific cytotoxic T lymphocytes depends on baseline CD4+ immunity to mediate durable responses.

Blood Adv 2021 01;5(2):496-503

Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY.

Adoptive cell therapy using cytomegalovirus (CMV)-specific cytotoxic T lymphocytes (CMV-CTLs) has demonstrated efficacy posttransplant. Despite the predicted limited engraftment of CMV-CTLs derived from third-party donors, partially matched third-party donor-derived CMV-CTLs have demonstrated similar response rates to those derived from primary hematopoietic cell transplantation donors. Little is known about the mechanisms through which adoptive cellular therapies mediate durable responses. Read More

View Article and Full-Text PDF
January 2021

Infectious Complications Predict Premature CD8 T-cell Senescence in CD40 Ligand-Deficient Patients.

J Clin Immunol 2021 May 26;41(4):795-806. Epub 2021 Jan 26.

Section of Rheumatology, Allergy and Immunology, Departments of Internal Medicine, Yale University School of Medicine, New Haven, CT, 06520, USA.

Purpose: CD40 ligand (CD40L)-deficient patients display increased susceptibilities to infections that can be mitigated with effective prophylactic strategies including immunoglobulin G (IgG) replacement and prophylactic antibiotics. CD8 T-cell senescence has been described in CD40L deficiency, but it is unclear if this is an intrinsic feature of the disease or secondary to infectious exposures. To address this question, we assessed CD8 T-cell senescence and its relationship to clinical histories, including prophylaxis adherence and infections, in CD40L-deficient patients. Read More

View Article and Full-Text PDF

Effect of everolimus-based drug regimens on CMV-specific T-cell functionality after renal transplantation: 12-month ATHENA subcohort-study results.

Eur J Immunol 2021 Apr 28;51(4):943-955. Epub 2020 Dec 28.

Department of Transplant and Infection Immunology, Saarland University, Homburg, Germany.

Post-transplant cytomegalovirus (CMV) infections and increased viral replication are associated with CMV-specific T-cell anergy. In the ATHENA-study, de-novo everolimus (EVR) with reduced-exposure tacrolimus (TAC) or cyclosporine (CyA) showed significant benefit in preventing CMV infections in renal transplant recipients as compared to standard TAC + mycophenolic acid (MPA). However, immunomodulatory mechanisms for this effect remain largely unknown. Read More

View Article and Full-Text PDF

Flow cytometric measurement of STAT5 phosphorylation in cytomegalovirus-stimulated T cells.

Cytometry A 2020 Dec 6. Epub 2020 Dec 6.

Institute of Clinical Immunology, Medical Faculty, University of Leipzig, Leipzig, Germany.

Cytomegalovirus (CMV)-specific T cells expand with CMV reactivation and are probably prerequisite for control and protection. Given the critical role STAT5A phosphorylation (pSTAT5A) in T cell proliferation, this study presents a simple and sensitive flow cytometric-based pSTAT5A assay to quickly identify CMV-specific T cell proliferation. We determined pSTAT5A in T cells treated with CMV-specific peptide mix (pp65 + IE1 peptides) from 20 healthy adult subjects and three immunodeficient patients with CARMIL-2 mutation. Read More

View Article and Full-Text PDF
December 2020

HIV Skews a Balanced Mtb-Specific Th17 Response in Latent Tuberculosis Subjects to a Pro-inflammatory Profile Independent of Viral Load.

Cell Rep 2020 12;33(9):108451

Laboratory of Immunology of HIV-TB Co-infection, Centre for Infectious Disease Research, Indian Institute of Science, Bangalore, India; Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, Faculty of Life Sciences & Medicine, Guy's Hospital, King's College London, London SE1 9RT, UK. Electronic address:

HIV infection predisposes latent tuberculosis-infected (LTBI) subjects to active TB. This study is designed to determine whether HIV infection of LTBI subjects compromises the balanced Mycobacterium tuberculosis (Mtb)-specific T helper 17 (Th17) response of recognized importance in anti-TB immunity. Comparative analysis of Mtb- and cytomegalovirus (CMV)-specific CD4 T cell responses demonstrates a marked dampening of the Mtb-specific CD4 T cell effectors and polyfunctional cells while preserving CMV-specific response. Read More

View Article and Full-Text PDF
December 2020

Cell therapy for cytomegalovirus infection.

Expert Opin Biol Ther 2021 May 21;21(5):649-659. Epub 2020 Dec 21.

UCL Cancer Institute, London, UK.

Introduction: Cytomegalovirus (CMV) infection is widely prevalent but mostly harmless in immunocompetent individuals. In the post hematopoietic stem cell transplant (HSCT) setting unrestricted viral replication can cause end-organ damage (CMV disease) and, in a small proportion, mortality. Current management strategies are based on sensitive surveillance programmes, with the more recent introduction of an effective prophylactic antiviral drug, letermovir, but all aim to bridge patients until reconstitution of endogenous immunity is sufficient to constrain viral replication. Read More

View Article and Full-Text PDF